Using a modified poliovirus to enhance cancer immunotherapy
Official title: Resolving Spatiotemporal Dynamics of Recombinant Poliovirus Immunotherapy
Funded at Duke University · NIH-11043500 · Data updated 2026-11-12
This study is exploring how a safe version of the poliovirus can help boost your immune system to better fight cancer by getting special immune cells to work harder at targeting and destroying cancer cells, and you might have the chance to be part of this exciting new treatment approach!
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | July 28, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $73,640 |
| NIH project number | 3R01CA281320-02S1 |
| Project ID | NIH-11043500 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with specific types of cancer who may benefit from enhanced immunotherapy approaches.
✕Less likely to help
Patients with non-cancerous conditions or those who do not have a suitable immune response may not benefit from this research.
What this research studies
This research investigates how a modified poliovirus can be used to improve the immune system's ability to fight cancer. It focuses on a specific type of immune cell, called dendritic cells, which play a crucial role in presenting tumor antigens to the immune system. By using a safe version of the poliovirus, the study aims to stimulate these dendritic cells to activate other immune cells that can target and destroy cancer cells more effectively. Patients may have the opportunity to contribute to this innovative approach to cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that harness the body's immune system to fight tumors.
How similar studies have gone: Previous research has shown promising results using similar viral approaches in cancer immunotherapy, indicating potential for success in this novel application.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Gromeier, Matthias — Duke University
- Study coordinator: Gromeier, Matthias
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.